Press Room (Corporate News) MediaRoom ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause * Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL Sun, 11 Nov 2018 08:15:00 -0500 New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial * Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001) Wed, 07 Nov 2018 17:00:00 -0500 FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis Tue, 06 Nov 2018 08:00:00 -0500 Sanofi Q3 2018 Performance Confirms Return to Growth Wed, 31 Oct 2018 08:00:00 -0400 FDA grants priority review for Sanofi's dengue vaccine candidate Tue, 30 Oct 2018 17:12:00 -0400